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Cytokine-induced inside-out activation of FcaR (CD89) is mediated by a single
serine residue (S263) in the intracellular domain of the receptor
Madelon Bracke, Jan-Willem J. Lammers, Paul J. Coffer, and Leo Koenderman
Fc receptors play an important role in
leukocyte activation and the modulation
of ligand binding (“activation”) is a criti-
cal point of regulation. Previous studies
demonstrated that the Fc receptor for IgA
(FcaRI/CD89) is regulated by cytokine
stimulation, switching it to a high-binding
state. To investigate the mechanism by
which cytokine-induced signal transduc-
tion pathways result in FcaRI activation,
cell lines expressing various receptor mu-
tants were generated. Binding studies
indicated that truncation of the C-termi-
nus of the FcaRI resulted in constitutive
IgA binding, removing the need for cyto-
kine stimulation. Furthermore, mutagen-
esis of a single C-terminal serine residue
(S263) to alanine (S>A) (single-letter
amino acid codes) also resulted in consti-
tutive IgA binding, whereas a serine to
aspartate (S>D) mutation was no longer
functional. The role of S263 might be in
regulating the interaction with the cy-
toskeleton, because disruption of the cy-
toskeleton results in reduced IgA binding
to both FcaRwt and FcaR_S>A. In addi-
tion, overexpression of a membrane-
targeted intracellular domain of FcaR,
and the introduction of cell-permeable
CD89 fusion proteins blocked IgA bind-
ing, implying a competition for endoge-
nous proteins. The proposal is made that
Fc receptors are activated by cytokines
via an inside-out mechanism converging
at the cytoplasmic tail of these receptors.
(Blood. 2001;97:3478-3483)
© 2001 by The American Society of Hematology
Introduction
Transmembrane receptors specific for the Fc region of immuno-
globulins, Fc receptors (FcRs), play an important role in leukocyte
activation by the recognition and binding of opsonized particles
during inflammatory processes.1 Specific FcRs exist for all 5
classes of human immunoglobulins. The best studied FcRs are the
leukocyte receptors for IgG (FcgR) and IgE (FceR), due to early
isolation of their genes and the availability of anti-FcR antibod-
ies.2,3 Relatively little is known about the receptor(s) for IgA
(FcaR). FcaRI (CD89) has been described to be expressed on
many cell types, including monocytes/macrophages, neutrophils,
and eosinophils4-7; however, little is known about its regulation
and functioning.6,7
We have previously demonstrated that activation of the FcR for
IgA (FcaR) and IgG (FcgRII) on primary human eosinophils is
regulated by Th2-derived cytokines, such as interleukin (IL)-4 and
IL-5.8,9 Cytokine stimulation leads to an increase in ligand binding,
without changing the levels of receptor expression, suggesting that
stimulation with cytokines regulates either the affinity or avidity
of FcR.8-10
To understand the mechanism by which FcR activation is
regulated, we have studied the regulation of the human FcR for IgA
(FcaR/CD89) by cytokines in a murine pre-B (Ba/F3) model
system as well as in primary human eosinophils. By expressing
various receptor mutants we demonstrate that the intracellular
domain of FcaRI is important for its regulation by cytokines.
Furthermore, we also present data showing that the cytoskeleton is
important for correct FcR activation. Our data demonstrate that this
process of cytokine-induced inside-out signaling is similar to that
observed in the regulation of the integrin family of cell surface
adhesion receptors.11-13 This inside-out signaling regulating FcRs is
a rapid mechanism that allows cells to respond quickly to their
environment.
Materials and methods
Reagents and antibodies
Ficoll-paque and Percoll were obtained from Pharmacia (Uppsala, Swe-
den). N-formyl-methionyl-leucyl-phenylalanine (fMLP) was purchased
from Sigma Chemical (St Louis, MO). Human serum albumin (HSA) was
from the Central Laboratory of the Netherlands Red Cross Blood Transfu-
sion Service (Amsterdam, The Netherlands). Purified human serum IgA
(. 20 mg/mL) was obtained from Cappel (Malvern, PA). It contained no
detectable trace of IgG, IgM, or nonimmunoglobulin serum proteins.
Recombinant human IL-5 was a gift from Dr M. McKinnon, GlaxoWell-
come (Stevenage, United Kingdom). Recombinant mouse IL-3 was pro-
duced in COS cells.14 For the detection of FcaR (CD89) with a FACSvan-
tage flow cytometer we used a specific phycoerythrin (PE)-conjugated
monoclonal antibody A59 (A59-PE, Pharmingen, Torrey Pines, CA).
Specific HIV-tat coupled peptides for inhibition studies were purchased
from Eurogentec (Lie`ge, Belgium). Cytochalasin D was ordered from
Sigma Chemical.
FcaR mutants
The FcaRwt and FcaR mutants were cloned into a pMT2 vector containing
a VSV-epitope tag. Human FcaR (in pSG513)15 was used as a template and
several substitution and deletion constructs were generated via polymerase
From the Department of Pulmonary Diseases, University Hospital Utrecht, The
Netherlands.
Submitted July 13, 2000; accepted January 16, 2001.
Supported by a research grant of the Netherlands Asthma Foundation (NAF
94.44).
Reprints: Leo Koenderman, Department of Pulmonary Diseases, F02.333,
University Hospital Utrecht, Postbus 85500, 3508 GA Utrecht, The
Netherlands; e-mail: l.koenderman@hli.azu.nl.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734.
© 2001 by The American Society of Hematology
3478 BLOOD, 1 JUNE 2001 z VOLUME 97, NUMBER 11
chain reaction (PCR) using the following primers: FcaRwt (Fwt: GCTGT-
CAGCACGATGGAC and Rwt: TTCACCTCCAGGTGTTTA), FcaRS263A
(Fwt and RS.A: CTTGCAGACAGCTGGTG), FcaRS263D (Fwt and RS.D:
CTTGCAGACATCTGGTG), FcaRDic (Fwt and RD229: GTGCCAAT-
TTTCAACCAG) and FcaRD262 (Fwt and RD262: TGGTGTTCGTG-
CAAAGGT). Gag-FcaR (aa226-266) and gag-D262 (aa226-262) constructs
were generated using pMT2_FcaRwt_VSV and pMT2_FcaRD262_VSV as
a template and PCR was performed with Fgag (GAAAATTGGCACAGC)
and Rgag (TCTAGATTACTTTC) primers. PCR products were cloned into
pCDNA3, via a vector that contained the murine Moloney leukemia virus
(MuMoLV) gag sequence.16 The intracellular domains of FcaRwt and
FcaRS263A were fused to GST. Constructs were generated using
pMT2_FcaRwt_VSV and pMT2_FcaRS.A_VSV as a template and per-
forming PCR with FGST (GAAAATTGGCACAGCC) and Rwt or RS.A
primers. PCR products were cloned into a pRP265 glutathione vector and
proteins were expressed in Escherichia coli. All construct were verified
by sequencing.
Generation of stable transfectants
The Ba/F3 cells were cultured at a cell density of 105 to 106 cells/mL in
RPMI 1640 supplemented with 8% Hyclone serum (Gibco, Rockville, MD)
and recombinant mouse IL-3. For the generation of polyclonal transfectants
pMT2_VSV containing FcaRwt or mutants were electroporated into Ba/F3
cells (0.28 V; capacitance 960 mFD) together with pSG5-CMV-Hygro
containing the hygromycin resistance gene. Cells were cultured in the
presence of IL-3 and selected in 500 mg/mL hygromycin (Boehringer
Mannheim, Mannheim, Germany). After 2 weeks of selection, cells were
tested for FcaR expression and positive cells were sorted with a FACSvan-
tage flowcytometer (Becton and Dickinson Immunocytometry Systems,
Mountain View, CA). Briefly, FcaR transfected Ba/F3 cells were incubated
with the PE-conjugated monoclonal antibody (mAb) A59 (A59-PE) for 30
minutes at 4°C. Fluorescence of the cells was quantified with the flow
cytometer and A591 cells were sorted and cultured. In this way polyclonal
cell lines expressing either FcaRwt, deletion mutants Dic and D262, or
substitution mutants S263A and S263D were generated. Ba/F3_FcaRwt
cells, expressing FcaRwt_VSV were subsequently used for transfection of
pCDNA3 containing either gag_FcaR or gag-D262. Cells were cultured
with mouse IL-3 and 500 mg/mL G418 (Boehringer Mannheim) to select
resistance. Stable cell lines were grown continually on murine IL-3, G418,
and hygromycin. Expression of FcaR was checked regularly with the
flow cytometer.
Isolation of eosinophils
Blood was obtained from healthy volunteers from the Red Cross Blood
Bank, Utrecht, The Netherlands. Eosinophils were isolated as described
previously17 and resuspended in incubation buffer (20 mM Hepes, 132 mM
NaCl, 6.0 mM KCl, 1.0 mM MgSO4, 1.2 mM KH2 PO4, supplemented with
5 mM glucose, 1.0 mM CaCl2, and 0.5% [wt/vol] HSA). Purity of
eosinophils was 97% (6 0.5 SEM), and recovery was usually 60% to 70%.
IgA-binding assays
The IgA-binding assays were performed either with purified human
eosinophils or with cytokine-starved Ba/F3 cells. For IL-3 starvation, Ba/F3
cells were washed twice with phosphate-buffered saline (PBS) and left in
medium (RPMI 1640 with 0.5% serum) without IL-3 for 4 hours. Prior to
performing a binding assay, Ba/F3 cells or purified eosinophils were
washed with Ca11-free incubation buffer containing 0.5 mM EGTA and
brought to a concentration of 8 3 106 cells/mL. A 50-mL cell suspension
(0.4 3 106 cells) was incubated at 37°C, with or without cytokines. Ba/F3
cells were preincubated with IL-3 (1:1000; 15 minutes). Human eosinophils
were stimulated with IL-5 with a final concentration of 1029 M. After
stimulation of the cells, Dynabeads coated with serum IgA (10 mg/mL) as
described previously17 were added in a ratio of 3.5 beads/cell. After briefly
mixing, the cells and beads were pelleted for 15 seconds at 100 rpm and
incubated for 30 minutes at 37°C. After incubation cells were resuspended
vigorously and IgA binding was evaluated under a microscope. All cells that
had bound 2 beads or more were defined as rosettes. One hundred cells were
scored and the number of beads that were bound to the cells was counted.
The amount of beads bound to a total of 100 cells (bound and unbound to
beads) was designated as the rosette index. As described previously, the
rosetting method with magnetic beads is specific because there is no
appreciable background binding of cells to beads coated with ovalbumin.18,19
Inhibition of IgA binding
Cytochalasin D was used to study the involvement of the cytoskeleton.
Cytokine-starved Ba/F3 cells or freshly isolated eosinophils were preincu-
bated with cytochalasin D (1 or 10 mM) for 10 minutes prior to cytokine
stimulation.
Specific tat-peptides were designed for inhibition studies. These pep-
tides consist of a 12–amino acid sequence of the HIV-tat peptide,18,20
necessary for entering a cell, coupled to either a specific amino acid
sequence of FcaR (C-terminal aa254-266) or a scrambled sequence (SCR).
The following tat-peptides were purchased from Eurogentec: tat_FcaR
(YGRKKRRQRRRG-PGLTFARTPSVCK), tat_S263A (YGRKKRRQR-
RRG-PGLTFARTPAVCK) and tat_SCR (YGRKKRRQRRRG-PSFVLAP-
KGRTCT). Before stimulation cells were incubated for 10 minutes at 37°C
with these peptides at a concentration of 100 mM. After stimulation
IgA-binding assays were performed as described above.
In vitro kinase assay
Fusion proteins, consisting of the intracellular domain of FcaRwt or
FcaR_S.A coupled to GST, were used as substrates for in vitro kinase
assays. Equal amounts of GST proteins were precoupled to glutathione
beads for 30 minutes at 4°C, and washed prior to use. Cytokine-starved
Ba/F3 cells (5 3 106) and freshly isolated human eosinophils (5 3 106)
were lyzed in 50 mL lysis buffer (50 mM Tris-HCl, pH 7.5,100 mM NaCl, 5
mM EDTA, 1% Triton X-100) supplemented with aprotinin (10 mg/mL),
leupeptin (10 mg/mL), and 1 mM phenylmethylsulfonyl fluoride (PMSF).
After addition of 450 mL kinase buffer (25 mM Tris, pH 7.4, 25 mM MgCl2,
50 mM rATP, 3 mCi g32P]-ATP), lysates were incubated with GST substrates
for 30 minutes at room temperature. Samples were washed 8 3 with lysis buffer
before addition of 5 3 Laemmli sample buffer and analyzed by electrophore-
sis on 15% sodium dodecyl sulfate–polyacrylamide gels. Substrate phosphor-
ylation was detected by autoradiography.
Results
The cytoplasmic domain of FcaR is important for
cytokine-induced ligand binding
We have previously shown that ligand binding to FcRs on human
eosinophils is modulated by cytokine-induced activation of PI3K.19
To understand how the PI3K-mediated signal from the cytokine
receptor can modulate the function of FcaRI (CD89), we generated
stable cell lines expressing intracellular deletion mutants of FcaR
in Ba/F3 cells. As shown in Figure 1A, deletion mutant FcaRIDic
lacks the complete intracellular domain (from aa229), whereas in
FcaRID262 the 4 C-terminal amino acids (aa263-266) were
deleted. Cells transfected with FcaRI or mutants were stained with
CD89 antibody (A59-PE) and sorted with a FACS flow cytometer,
to obtain polyclonal cell lines expressing high levels of FcaRI
(CD89) (Figure 1B). As shown in Figure 1C, cells expressing
FcaRwt did not bind IgA beads when IL-3 had been removed for 4
hours (Figure 1C, white bar). In contrast, addition of IL-3 to these
cells resulted in a high level of IgA binding. Expression of the
mutant FcaRIDic resulted in constitutive IgA binding that was not
modulated by cytokines (Figure 1C). We generated several deletion
mutants of the receptor to locate the region whereby cytokine-
induced control of the receptor was mediated. It turned out that
deletion of C-terminal amino acids 262 to 266 resulted in an
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increase in IgA binding. Interpretation of data obtained with
deletion mutants can be complicated by nonspecific structural
changes of the receptor. Therefore, we examined whether S263
might be important for receptor activation, because this 4–amino
acid stretch (262-266) contains a serine residue at this position. As
shown in Figure 2, substitution of the serine residue by an alanine
residue (FcaRS.A) resulted in an FcaRI that constitutively binds
IgA (Figure 2C), independently of cytokine stimulation. In con-
trast, mutation of S263 to an aspartic acid led to a receptor that
could only weakly bind IgA, even after cytokine stimulation
(Figure 2C).
Because a negatively charged aspartic acid might mimic the
phosphorylation of this residue, we hypothesized that phosphoryla-
tion of S263 may be involved in the negative regulation of FcaRI.
Phosphorylation of the intracellular domain of FcaRI
To investigate whether FcaRI is indeed phosphorylated in resting
Ba/F3 cells or eosinophils, we performed in vitro kinase assays
with the intracellular domain of FcaRI as a substrate. Whole cell
lysates of IL-3–starved Ba/F3 cells (Figure 3A) and freshly isolated
eosinophils (Figure 3B) were incubated with the GST-coupled
intracellular domain of FcaRwt or FcaR_S.A. As shown in
Figure 3, the intracellular tail of FcaRwt was indeed phosphory-
lated by total lysates of unstimulated cells. In contrast, this
intracellular tail with an S.A substitution on residue 263 was not
phosphorylated by either of the cell lysates (Figure 3, right lanes).
These data suggest that the phosphorylation state of S263 may
indeed contribute to the regulation of ligand-binding to FcaR.
Involvement of the cytoskeleton in FcaRI activation
The mechanism of cytokine-induced inside-out signaling of FcaRI
appears to be similar to the regulation of integrin activation.11-13
Integrin regulation by inside-out signaling is well established,
although different signaling pathways are involved in regulation of
different integrins, depending on the cellular context and the
activation stimuli used. Interactions of integrins with the cytoskel-
eton are also thought to be important for their (in)activation.12,18 To
investigate whether the cytoskeleton may also be critically in-
volved in the regulation of FcRs, we studied the importance of an
intact cytoskeleton for correct FcaRI functioning. Incubation of
cells with cytochalasin D enabled us to study the effect of
disrupting the cytoskeleton on FcaR activation in both Ba/F3 cells
(Figure 4A) and primary eosinophils (Figure 4B). As shown in
Figure 4A, cytokine-stimulated Ba/F3_FcaRI cells did not bind
IgA when they were pretreated with cytochalasin D, suggesting that
correct assembly of cytoskeletal proteins is necessary for activation
of FcaRI. Interestingly, FcaR_S.A also could not bind IgA after
cytochalasin D treatment. Comparable with Ba/F3_FcaRI cells,
binding to IL-5–treated eosinophils was also completely abolished
by disruption of cytoskeletal organization (Figure 4B). These data
suggest that besides the phosphorylation state of S263, the
interaction of FcaRI with the cytoskeleton is also crucial for
correct activation.
Overexpression of the FcaRI cytoplasmic domain inhibits IgA
binding to the full-length receptor
Because the intracellular domain of FcaRI was critical for ligand
binding, we were interested in studying whether overexpression of
the intracellular tail of FcaRI could inhibit the activation of the
receptor. This would implicate the involvement of an associating
protein in the activation of the receptor. To specifically express the
cytoplasmic tail at the membrane, we coupled the intracellular
domain of FcaRI to the viral gag-sequence from MuMoLV.16 As a
result of myristoylation of this gag-sequence, a fusion protein is
targeted to the membrane. In this way, we overexpressed mem-
brane targeted gag-fusions with either the complete intracellular
domain of FcaRI (gag_wt) or the cytoplasmic domain lacking the
last 4 amino acids (gag_D262) (Figure 5A,B). Overexpression of
the complete intracellular domain abrogated the IL-3–dependent
up-regulation of IgA binding (Figure 5C). However, when the
intracellular region lacked the last 4 amino acids, there was no
inhibition of IL-3–induced FcaRI modulation. This suggested that
the overexpressed cytoplasmic domain can compete with the
full-length FcaRI for certain proteins necessary for proper recep-
tor regulation.
In contrast to Ba/F3 cells, eosinophils are refractory to DNA
Figure 1. The intracellular domain of FcaRI is impor-
tant for cytokine-induced IgA binding. (A) Schematic
diagrams of FcaRI and different FcaR-deletion mutants
are shown. (B) The expression of the receptors was
analyzed by flow cytometry. (C) Ba/F3 cells expressing
FcaRI mutants were used for IgA-rosette assays. Cells
were cytokine starved and subsequently stimulated for
15 minutes with either buffer (M) or IL-3 (u). IgA binding
to the cells was measured by the formation of rosettes
between cells and IgA-coated beads. Results are ex-
pressed as rosette index and as means 6 SE (n 5 3).
Figure 2. S263 is critical for FcaRI activation by
cytokines. (A) Schematic diagrams of FcaRI and differ-
ent S263 substitution mutants are shown. (B) The expres-
sion of the different receptors was analyzed by flow
cytometry. (C) Ba/F3 cells expressing FcaRI mutants
were used for IgA-rosette assays. Cells were cytokine
starved and subsequently stimulated for 15 minutes with
either buffer (M) or IL-3 (gray bars). IgA binding to the
cells was measured by the formation of rosettes between
cells and IgA-coated beads. Results are expressed as
rosette index and as means 6 SE (n 5 3).
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transfection and to perform competition experiments in primary
cells, another approach was required. Recently, it has been
described that the coupling of peptides to a specific short amino
acid sequence of the tat protein of HIV results in the uptake of these
peptides into cells.18,20,21 We designed peptides consisting of this
tat-sequence fused to either the last 13 amino acids of FcaRIwt
(aa254-266), designated tat_FcaR, or to the same 13–amino acid
sequence with the S.A substitution at position 263 (tat_S.A) (Fig-
ure 6A). Furthermore, as a control the 13 amino acids of the
wt-peptide were scrambled and linked to the tat-sequence (tat_SCR).
As shown in Figure 6B, incubation of Ba/F3_FcaR cells with
tat_FcaR resulted in a concentration-dependent inhibition of IgA
binding on cytokine stimulation. Incubation with tat_S.A or
tat_SCR, however, did not influence the IL-3–induced IgA binding.
The activity of tat_S.A was specific because Mac-1–mediated
activation of the respiratory burst, which is also sensitive for
cytokine-induced inside-out control, was not inhibited by the
peptide (results not shown). Using these tat-peptides, it was also
possible to investigate the effect of FcaR mutants in primary
human eosinophils that are refractory to manipulation by either
transfection or viral infection. Similar to the effect on Ba/F3_FcaR
cells, binding of IgA beads to cytokine (IL-5)-primed eosinophils
was inhibited by preincubation with tat_FcaR, whereas neither the
S.A mutation nor the scrambled peptide had any effect (Figure
6C). We thus conclude that in a relevant myeloid cell-type
endogenously expressing FcaR, the process of modulation of the
receptor functionality via inside-out signaling also involves the
intracellular domain, with a critical role for S263.
Discussion
Cytokines, such as interleukins, are important regulators of cellular
activation, and it is described for human eosinophils that cytokines
are involved in the stimulation of many effector functions,21 such as
degranulation, respiratory burst, and activation of adhesion and
complement receptors. For the FcRs for IgA (FcaR) and IgG
(FcgRII) we have previously shown that binding of Ig-coated
targets to FcRs on eosinophils is dependent on cytokine stimulation
of the cells.8,9,19 Although the FcRs on eosinophils do not bind
monomeric ligand, the functional status of both FcaR and FcgRII
for complexed ligand is altered by Th2-derived cytokines such as
IL-4 and IL-5. Because this cytokine-mediated modulation is very
rapid,8 this switch is not likely to be due to de novo receptor
synthesis. Moreover, FACS analysis revealed that levels of receptor
expression on the membrane are not altered by cytokine stimula-
tion (M. Bracke, unpublished results, June 1999; Dustin and
Springer22).
In this study we used Ba/F3 cells as a model to study the
molecular mechanism of cytokine-induced ligand binding to FcaRI
(CD89). This murine pre-B cell line, Ba/F3, lacks endogenous
CD89 expression and these cells require IL-3 to survive, similar to
the requirement for IL-5/IL-3/granulocyte-macrophage colony-
stimulating factor (GM-CSF) for human eosinophil survival. In
contrast with other cell lines commonly used for FcR studies, such
as the murine pre-B IIA1.6 cells, Ba/F3_FcaRI cells interact with
IgA-coated targets in a cytokine-dependent fashion. Therefore,
Ba/F3 cells provide an excellent system to study FcR regulation.
From the work described in this report it is clear that FcaRI
activation requires the intracellular domain of the receptor. We
demonstrate that the IgA-binding subunit (CD89) of the FcaR does
not simply play a passive role in immunoglobulin binding but is
critical for correct regulation of receptor functioning. The concept
of inside-out signaling for FcRs is novel and it appears to be
comparable to the activation paradigm previously described for
integrins. Integrins consist of a and b subunits that are nonco-
valently associated in the membrane (reviewed in Hynes12). Studies
with chimeras containing the cytoplasmic domains of various a
and b subunits joined to the transmembrane and extracellular
domain of the platelet aIIbb3-integrin indicated that integrin
cytoplasmic domains transduce cell type–specific signals that
modulate ligand-binding affinity.23 Thus, integrin cytoplasmic tails
are targets for the modulation of integrin affinity. Here we show
that, analogous to integrin activation, inside-out signaling of FcaRI
also requires the intracellular domain of the receptor to modulate
the ligand binding extracellularly. Moreover, expression of deletion
Figure 4. Cytokine-induced activation is inhibited by cytochalasin D. Cytokine-
starved Ba/F3_FcaRI cells (A) or purified eosinophils (B) were incubated with buffer
(M) or with cytochalasin D for 10 minutes and subsequently stimulated or left
untreated. Ba/F3_FcaRI cells were incubated with IL-3 (1:1000; 15 minutes) (A) and
eosinophils were stimulated with IL-5 (1029M; 15 minutes) (B). Binding of IgA beads
to these cells was measured and results are expressed as rosette index (number of
beads/100 cells) and as means 6 SE (n 5 3).
Figure 3. Phosphorylation of the intracellular domain of FcaRI. The intracellular
domain of CD89 is constitutively phosphorylated in nonprimed cells. This phosphory-
lation is critically controlled by S263. GST-tagged intracellular domains of CD89 are
used for an in vitro kinase assay with eosinophil and Ba/F3 lysates. Hereafter,
constructs are “fished” with glutathione-coated beads and visualized by autoradiogra-
phy (upper panels) and protein staining for checking equal loading (lower panels).
The experiment shown is representative of 3 additional experiments.
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or substitution mutants of the cytoplasmic domain of FcaRI
revealed that cytokine-dependent modulation requires the C-
terminus of the receptor. Deletion of the cytoplasmic tail of FcaRI
results in a constitutive binding of ligand, independent of cytokine
stimulation. Furthermore, expression of FcaRI in cell lines, such as
fibroblasts or cytokine-independent pre-B cells (IIA1.6), results in
a receptor that contains a constitutive high activity state.15 In
unstimulated eosinophils and cytokine-starved Ba/F3 cells, FcaRI
is not activated. This suggests that there are cytoplasmic signaling
pathways that constitutively suppress FcaR activation in resting
eosinophils. In parallel, for integrins it has been suggested that
active cellular mechanisms are involved in inhibition of activation.
It has been described that activation of integrins on T cells is often
transient, even with continued stimulation, suggesting the existence
of an inhibitory signal that overrules the activation signal.24,25 A
negative regulation has also been suggested to explain the highly
activated state of purified avb3-integrin, in contrast with the
moderate affinity state of cellular avb3.26 Comparable, cytokine-
induced activation of immunoglobulin receptors on eosinophils is
likely to be caused by inhibition of an active signal, which normally
keeps the receptor in a nonfunctional state. This mechanism is
important in preventing activation of the cells in circumstances
where activation is not required and could even be harmful.
It has been described for b1-integrins that the phosphorylation
state of a conserved C-terminal serine is important role for the
activation state of the receptor. In cells that undergo mitosis,
phosphorylation of this sering residue of b1-integrin leads to
inactivation of the integrin resulting in the cells losing adhe-
sion.12,27,28 In this report we show that substitution of a C-terminal
serine (S263) affects the activation state of FcaRI. It is difficult to
study the phosphorylation state of S263 specifically, because the
very short cytoplasmic tail of FcaRI contains several possible
phosphorylation sites and tryptic mapping is not possible. In
addition, eosinophils are nonproliferative primary cells that could
not be labeled with radioactivity. Moreover, it is also not possible to
immunoprecipitate endogenous FcaRI from eosinophils. To circum-
vent problems with eosinophils and to compare the phosphoryla-
tion status of FcaRI both in Ba/F3 cells and primary human
eosinophils, we used another approach. We used the intracellular
domain of FcaRI as a substrate for in vitro kinase assays. As
suggested from Figures 1 and 2, the intracellular domain of FcaRI
is indeed phosphorylated (Figure 3A,B, middle lanes). In contrast,
a substitution mutant of S263 cannot be phosphorylated by lysates
from resting cells, suggesting that this residue indeed is phosphory-
lated in cytokine-starved or resting cells. An interesting possibility
is that dephosphorylation of S263 is the first step in activation of
the receptor, subsequently followed by other steps leading to a
change in conformation and a fully functional receptor. However,
addition of cytokines to Ba/F3 cells and eosinophils did not lead to
an inhibition of this in vitro kinase assay implying that the level of
control is not simply by inhibition of this kinase activity (results not
shown). We speculate that proteins associating with the C-terminus
of FcaRI are involved in this cytokine-mediated regulation,
because overexpression of the intracellular domain of the receptor
leads to inappropriate binding of IgA beads. In contrast, a
tat-peptide with the S.A mutation (Figure 6B,C) is not competi-
tive, and therefore it is tempting to speculate that activation by
cytokines leads to dissociation of interacting proteins or dephosphor-
ylation of S263, subsequently resulting in a functional FcaRI that
is able to bind IgA beads.
In addition to (de)phosphorylation of the receptors, interactions
with the cytoskeleton are also thought to contribute to integrin
activation by stabilizing an active conformation.28 However, there
are also reports that interactions of the cytoplasmic domain of
integrins with the cytoskeleton can lock integrins in an inactive
state.13,18,28 Interestingly, for FcaRI we also provide evidence that
the cytoskeleton might be important in maintaining FcaRI activa-
tion. Disruption of the cytoskeleton with cytochalasin D treatment
inhibits IgA binding to FcaR_S263A, suggesting that although the
mutation of S263 into alanine switched the receptor to a state of
constitutive high binding to IgA, this mutant receptor also requires
the interaction with the cytoskeleton. This concept is corroborated
by the finding that the lateral movement (determined by fluores-
cence recovery after photobleaching) of both wild-type and mutant
receptors is similar (results not shown). These findings argue
against a hypothesis that priming of FcaRI function is mediated by
Figure 5. Overexpression of the intracellular domain
of FcaRI inhibits the binding of IgA beads to Ba/F3
cells. Ba/F3_FcaRI cells overexpressing gag-tagged
FcaRI constructs (A) were checked for FcaRI expression
by FACS flow cytometry (B). Cells were used for IgA-
binding assays and were cytokine starved and stimulated
with either buffer (M) or IL-3 (u) (C). After stimulation
rosette assays were performed, and binding of IgA beads
was counted. Results are expressed as rosette index
(number of beads/100 cells) and as means 6 SE (n 5 3).
Figure 6. Overexpression of the intracellular domain
of FcaRI by cell permeable tat-peptides inhibits the
binding of IgA beads to Ba/F3 cells and human
eosinophils. Overexpression of the intracellular domain
was also obtained with tat-peptides (A). Both cytokine-
starved Ba/F3_FcaRI cells (B) and purified human eosin-
ophils (C) were incubated with 100 mM of the tat-FcaRI
(wt), tat_S.A or a nonrelevant scrambled peptide (tat-
SCR). After stimulation for 15 minutes of the Ba/F3 cells
with IL-3 (1:1000) and the eosinophils with IL-5 (1029M),
rosette assays were performed, and binding of IgA beads
was counted. Results are expressed as rosette index
(number of beads/100 cells) and as means 6 SE (n 5 3).
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an increased avidity due to enhanced lateral movement of the
receptor. In addition, these data again show the importance of the
interaction between cytoskeleton and opsonin and integrin receptors.
It is tempting to speculate that FcaRI, which is phosphorylated
in unstimulated cells, will become dephosphorylated on cytokine
stimulation and allow interaction with the cytoskeleton, stabilizing
the receptor in an activated state. Although further experiments will
be necessary to determine the precise nature of this mechanism, we
clearly show that the very short intracellular tail of FcaRI plays a
crucial role in the IgA-binding switch. Moreover, the phosphoryla-
tion state of the C-terminal serine-residue (S263) in this intracellu-
lar tail of FcaRI appears to be critical for a proper regulation of the
receptor. It appears that FcaRI does not simply bind ligand but that
it is critical for cytokine-dependent regulation of IgA binding to
the cell.
Cytokine-induced “inside-out” signaling switches FcaRI to an
active state and subsequent ligand binding will lead to FcR-g
chain-mediated “outside-in” signaling, resulting in cell activation.
In this way, leukocytes can respond very rapidly and efficiently to
their environment, a process that requires tight regulation. A greater
understanding of cytokine-mediated modulation of FcR function-
ing on leukocytes will generate insight into the regulation of
leukocyte activation and the pathogenesis of inflammation, possi-
bly providing novel therapeutic options, such as inhibiting eosino-
phil activation in the lungs of allergic asthmatics.
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